SLC9A5: A Promising Gene for Cancer Treatment and Research (G6553)

Target Name: SLC9A5

NCBI ID: G6553

SLC9A5

SLC9A5: A Promising Gene for Cancer Treatment and Research

SLC9A5 (NHE-5) is a gene that encodes a protein known as NHE-5. NHE-5 is a member of the NHE gene family, which is responsible for the production of a group of proteins known as nucleotideases. These proteins are involved in the breakdown of nucleic acids, which is a critical process in the regulation of gene expression and DNA replication.

SLC9A5 is a splicing variant of the NHE-5 gene, which means that it has different genetic material than the standard NHE-5 gene. SLC9A5 has been shown to have unique functions in various organisms, including humans. For example, studies have shown that SLC9A5 is involved in the regulation of cell division and differentiation, and that it plays a role in the development and progression of certain diseases.

One of the most promising aspects of SLC9A5 is its potential as a drug target. The NHE-5 gene has been shown to be involved in a variety of cellular processes, including cell signaling, DNA replication, and cell division. Therefore, drugs that can modulate these processes may be effective in treating a wide range of diseases.

One approach to targeting SLC9A5 is to use small molecules that can interact with the protein. This approach is based on the idea that drugs that mimic the natural activity of the protein can be effective in blocking its function. One of the most promising small molecules that has been shown to interact with SLC9A5 is calledinvest-12018602. This molecule is known to be a potent inhibitor of SLC9A5, and has been shown to be effective in treating certain types of cancer.

Another approach to targeting SLC9A5 is to use antibodies that are designed to selectively bind to the protein. This approach is based on the idea that antibodies can be used to target specific regions of the protein and block its function. One of the most promising antibodies that has been shown to interact with SLC9A5 is called monoclonal antibody 12F10. This antibody is known to be highly specific for SLC9A5, and has been shown to be effective in treating certain types of cancer.

In addition to its potential as a drug target, SLC9A5 is also a potential biomarker. The NHE-5 gene is known to be expressed in a variety of tissues and cells, including cancer cells. Therefore, measuring the level of SLC9A5 in these cells or tissues could be a useful diagnostic or predictive marker for certain types of cancer.

Overall, SLC9A5 is a promising gene that has the potential to be a drug target or biomarker. Further research is needed to fully understand its functions and potential applications in medicine.

Protein Name: Solute Carrier Family 9 Member A5

Functions: Plasma membrane Na(+)/H(+) antiporter. Mediates the electroneutral exchange of intracellular H(+) ions for extracellular Na(+) in 1:1 stoichiometry, thus regulating intracellular pH homeostasis, in particular in neural tissues (PubMed:9933641, PubMed:10692428, PubMed:19276089, PubMed:24936055). Acts as a negative regulator of dendritic spine growth (PubMed:21551074). Plays a role in postsynaptic remodeling and signaling (PubMed:24006492, PubMed:21551074). Can also contribute to organellar pH regulation, with consequences for receptor tyrosine kinase trafficking (PubMed:24936055)

The "SLC9A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets